Duality Biotherapeutics, Inc. (ticker: DUALITYBIO-B) has announced that its board of directors will convene on 28 August 2026 to consider and approve the unaudited financial results for the six months ended 30 June 2026. The meeting will also address matters related to the public release of the interim report.

The board currently consists of eight members, including Executive Directors Dr. Zhu Zhongyuan (Chairman and CEO), Mr. Zhang Shaoren, and Dr. Hua Haiqing; Non-Executive Directors Mr. Cai Zhiyang and Dr. Yu Tao; and Independent Non-Executive Directors Mr. Xie Dong, Mr. Gao Fengyong, and Ms. Chuai Shuyin.

The company affirmed that Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited assume no responsibility for the announcement’s contents.